Patrick Dillon, MD
Medical Oncology · Charlottesville, VANPI 1952502718
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (53.9%), food and beverage and grants — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Novartis at 53.9% of the total. Reporting peaked in 2022 at $453 and has fallen 82.6% since, to $79 in 2025.
Across 16 payments — averaging $84.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$732
- AstraZeneca$250
- Seagen Inc.$104
- GSK$87
- Lilly USA, LLC$79
- Tesaro, Inc.$76
- plus $30 from 2 others
Across 345 payments — averaging $7467.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$827K
- Seagen Inc.$584K
- AstraZeneca$304K
- Radius Health, Inc.$238K
- Tesaro, Inc.$216K
- Pfizer$189K
- plus $218K from 7 others
What the payments were for
- Grants$25018%
- Food & beverage$34626%
- Education$302%
- Other$73254%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 8 | $732 |
| AstraZeneca | 1 | $250 |
| Seagen Inc. | 1 | $104 |
| GSK | 1 | $87 |
| Lilly USA, LLC | 1 | $79 |
| Tesaro, Inc. | 2 | $76 |
| Merck | 1 | $18 |
| Gilead | 1 | $12 |
How this compares
$1,359 in reported general payments places this provider in the 55th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 30 | $465,259 |
| VerzenioAbemaciclib | 22 | $338,963 |
| Letrozole | 139 | $3,343 |
| Tamoxifen Citrate | 43 | $1,100 |
| Dexamethasone | 22 | $368 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $258 |
| Prochlorperazine Maleate | 20 | $247 |
| Anastrozole | 15 | $227 |
| Ondansetron Hcl | 26 | $190 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $150 |
| Prednisone | 11 | $88 |
| Oxycodone Hcl | 11 | $74 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $732 | $465,25930 claims |
| Lilly USA, LLCVerzenio | $79 | $338,96322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 95 medical oncology providers in Virginia.
Other medical oncology in Charlottesville
- Robert DreicerCharlottesville$296K
- Ryan GentzlerCharlottesville$62K
- Matthew ReilleyCharlottesville$37K
- Enrica MarchiCharlottesville$30K
- Richard HallCharlottesville$29K
- Paul ViscuseCharlottesville$12K
- Ludimila CavalcanteCharlottesville$7K
- William SkeltonCharlottesville$6K
- Paul KunkCharlottesville$4K
- John WagnerCharlottesville$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.